A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn

Journal of Perinatology

Volumn 32, Issue 8, 2012, Pages 608-613

  Mohamed, W A ^a,b   Ismail, M ^c,d  

^a MINIA UNIVERSITY   (Egypt)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

^c ZAGAZIG UNIVERSITY   (Egypt)

^d KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

bosentan; neonates; persistent pulmonary hypertension

Indexed keywords

BOSENTAN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LUNG ARTERY PRESSURE; MALE; NEUROLOGIC DISEASE; NEWBORN; NEWBORN CARE; OUTCOME ASSESSMENT; PERSISTENT PULMONARY HYPERTENSION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84864464143     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2011.157     Document Type: Article

References (21)

1. Morin III FC, Stenmark KR. Persistent pulmonary hypertension of the newborn: state of the art. Am J Respir Crit Care Med 1995; 151: 2010-2032.
2. Steinhorn RH, Millard SL, Moran III FC. Persistent pulmonary hypertension of the newborn: role of nitric oxide and endothelin in pathophysiology and treatment. Clin Perinatol 1995; 22: 405-428.
3. Konduri GG. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 2004; 31: 591-611. (Pubitemid 39119487)
4. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr 2001; 160: 217-222. (Pubitemid 32250001)
5. Ivy DD, Le Cras TD, Horan MP, Abmen SH. Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension. Am J Physiol 1998; 274(Part 1): L535-L541.
6. Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr 1993; 123: 109-114. (Pubitemid 23185211)
7. Christou H, Adatia I, Van Marter L, Kane JW, Thompson JE, Stark AR et al. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5-monophosphate concentration in newborn infants with persistent pulmonary hypertension. J Pediatr 1997; 130: 603-611. (Pubitemid 27492652)
8. Walsh MC, Stork EK. Persistent pulmonary hypertension of the newborn. Clin Perinatol 2001; 28: 609-627.
9. Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr 2009; 98: 1683-1685.
10. Galie N, Hinderliter A, Torbicki A, Fourme T, Simonneau G, Pulido T et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386. (Pubitemid 36439000)
11. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
12. Barst R, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A et al. Pharmacokinetics, safety, and efficacity of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382. (Pubitemid 36403597)
13. Goissen C, Ghyselen L, Tourneux P, Krim G, Storme L, Bou P et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr 2008; 167: 437-440. (Pubitemid 351322478)
14. Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr 2011 e-pub ahead of print 8 March 2011; doi:10.1007/s00431-011-1422-9.
15. Ostrea EM, Villanueva-Uy ET, Natarajan G, Uy HG. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr Drugs 2006; 8: 179-188. (Pubitemid 43927187)
16. Deakins KM. Bronchopulmonary dysplasia. Respir Care 2009; 54: 1252-1262.
17. Ichiba H, Matsunami S, Itoh F, Ueda T, Ohsasa Y, Yamano T. Three-year follow up of term and near-term infants treated with inhaled nitric oxide. Pediatr Int 2003; 45: 290-293. (Pubitemid 36995100)
18. Latini G, Del Vecchio A, De Felice C, Verrotti A, Bossone E. Persistent pulmonary hypertension of the newborn: therapeutical approach. Mini Rev Med Chem 2008; 8: 1507-1513.
19. Nassi N, Daniotti M, Agostiniani S, Lombardi E, Favilli S, Donzelli GP. Sildenafil as "first line therapy" in pulmonary persistent hypertension of the newborn? J Matern Fetal Neonatal Med 2010; 23(S3): 104-105.
20. Kusuda S, Shishida N, Miyagi N, Hirabayashi M, Kim TJ. Cerebral blood flow during treatment for pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 1999; 80: F30-F33. (Pubitemid 29129594)
21. Leavitt AM, Watchko JF, Bennett FC, Folsom RC. Neurodevelopmental outcome following persistent pulmonary hypertension of the neonate. J Perinatol 1987; 7: 288-291.